Supplementary Figure S5



Supplementary Figure S5

CP-DN-ATF5 reduces *IL6* and *IL8* expression in LN229, HAP1, and HAP1 ATF5KO-1 cells. **A**. CP-DN-ATF5 reduces the expression of *IL6* and *IL8* mRNA in LN229 cells. Replicate cultures were exposed to the indicated concentrations of CP-DN-ATF5 for 24 hours and then assessed for relative levels of *IL6* and *IL8* transcripts. Values represent means ± SEM and were derived from 3 independent experiments carried out in triplicate. **P*<0.001 compared with corresponding control. **B**. CP-DN-ATF5 reduces expression of *IL6* mRNA in HAP1 cells irrespective of the presence of ATF5 expression. Replicate cultures were exposed to 100 μM CP-DN-ATF5 for 72 hours and then assessed for relative levels of *IL6* mRNA using two different primers. Values represent means ± SEM and were derived from 2 independent experiments carried out in triplicate. **P*<0.0001 compared with corresponding controls. ***P*=0.025 compared with WT control cells. ****P*=0.0045 compared with WT control cells. **C**. CP-DN-ATF5 reduces expression of *IL8* mRNA in HAP1 cells irrespective of the presence of ATF5 expression. Replicate cultures in one experiment were exposed to 100 μM CP-DN-ATF5 for 72 hours and then assessed for relative levels of *IL8* mRNA. Bar indicates man. **D**. Relative expression of *CEBPB* mRNA in WT and ATF5KO-1 HAP1 cells. Values represent means ± SEM and were derived from 2 independent experiments carried out in triplicate. **P*<0.001 compared with WT cells. **E**. Relative expression of

CEBPD mRNA in WT and ATF5KO-1 HAP1 cells. Values are for one experiment carried out with 3 cultures each. Bar indicates mean.